Wall St Engine(@wallstengine):Piper Sandler Upgrades $TEM to Overweight, Raises PT to $76 from $56 Three growth drivers that were previously difficult to underwrite are now increasingly visible: (1) the pending acquisition of Personalis gives Tempus ownership of a differentiated tumor-informed MRD platform; (2) the positive INTerpath-001 readout increases the strategic value of Personalis’ and TEM's role as the tumor sequencing provider for potentially a new therapeutic class; and (3) FDA approval of tumor-only xT CDx clears a key hurdle for Tempus to pursue unified ADLT pricing for xT, with xF potentially following in 2H27. Analyst: David Westenberg

2026.09.01 10:43

Piper Sandler Upgrades $TEM to Overweight, Raises PT to $76 from $56 Three growth drivers that were previously difficult to underwrite are now increasingly visible: (1) the pending acquisition of Personalis gives Tempus ownership of a differentiated tumor-informed MRD platform; (2) the positive INTerpath-001 readout increases the strategic value of Personalis’ and TEM's role as the tumor sequencing provider for potentially a new therapeutic class; and (3) FDA approval of tumor-only xT CDx clears a key hurdle for Tempus to pursue unified ADLT pricing for xT, with xF potentially following in 2H27. Analyst: David Westenberg